New drug shrinks tumors in some breast cancer patients

NCT ID NCT04699630

Completed Disease control Sponsor: SCRI Development Innovations, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 study tested a drug called patritumab deruxtecan in 121 people with advanced or metastatic breast cancer. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The main goal was to see how many patients had their tumors shrink or disappear. Results showed some patients responded, but side effects were also reported.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Patritumab deruxtecan (U3-1402)
What this could lead to: If successful, this drug could offer a new treatment option for people with metastatic breast cancer, especially those who have not responded to other therapies.
What could go wrong: This is a phase 2 trial with only 121 participants, so results may not apply to everyone. Side effects are possible, and the drug may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LOCALLY ADVANCED BREAST CANCER METASTATIC BREAST CANCER

Contacts and locations

Locations

City of Hope

Duarte, California, 91010, United States
Florida Cancer Specialists-North

St. Petersburg, Florida, 33705, United States
Florida Cancer Specialists-South

Fort Myers, Florida, 33901, United States
Fred Hutchinson Cancer Center

Seattle, Washington, 98109, United States
Highlands Oncology Group

Springdale, Arkansas, 72762, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
Rutgers-Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
Tennessee Oncology

Nashville, Tennessee, 37203, United States
University of Alabama at Birmingham

Birmingham, Alabama, 35249, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.